News

SEATTLE, Wash and VANCOUVER, British Columbia, November 12, 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced third quarter 2020 financial results and provided an update on the cytisinicline clinical development program. Recent Events &…

SEATTLE, Wash. and VANCOUVER, British Columbia, October 29, 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third quarter 2020 financial results and provide an update on the cytisinicline development program on Thursday, November 12, 2020 at 4:30PM…

October 22, 2020. Dear Fellow Shareholders,. We hope this letter finds you and your families safe and healthy. Given that we continue to live in unprecedented times, faced with uncertainty and unique challenges, John and I thought it was appropriate to reach out with an update on the company’s progress. Achieve remains committed to prioritizing…

SEATTLE, Wash and VANCOUVER, British Columbia, October 8, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held…

SEATTLE, Wash. and VANCOUVER, British Columbia, September 3, 2020 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will present at two upcoming investor conferences. H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16th…